Interactions médicamenteuses de type pharmacocinétique avec les inhibiteurs d’ALK: Pharmacokinetic drug-drug interactions with ALK inhibitors

Abstract

The ALK inhibitors exhibit an inter-patient variability in clinical response (efficacy, toxicity). The pharmacokinetic variability is one of the factors contributing to this clinical variability. Patients treated with ALK inhibitors are candidates to drug-drug interaction since they are commonly polymedicated for the treatment of their comorbidities, pain and/or adverses events related to the antitumor treatment. Given ALK inhibitors exhibit a narrow therapeutic index, some pharmacokinetic drug-drug interactions can therefore result either in supra-therapeutic plasma concentrations raising the toxic risk or in infra-therapeutic concentrations leading to decreased efficacy. Besides, food or phytotherapy can also significantly altered the pharmacokinetics of some ALK inhibitors. This review focuses on the potential pharmacokinetic drug-drug interactions with ALK inhibitors.1877-1203/© 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.